Treating and Preventing HIV with Generic Drugs — Barriers in the United States

New England Journal of Medicine
January 25, 2018   Vol. 378 No. 4
http://www.nejm.org/toc/nejm/medical-journal

Treating and Preventing HIV with Generic Drugs — Barriers in the United States
Erika G. Martin, Ph.D., M.P.H., and Bruce R. Schackman, Ph.D.
Combination antiretroviral therapy (ART) has dramatically improved survival rates among people with HIV and is a mainstay of HIV prevention; evidence shows that durable viral suppression prevents the transmission of infection. In addition, preexposure prophylaxis (PrEP) is an emerging approach to preventing HIV acquisition for certain high-risk groups. Generic ART medications offer the potential for treating and preventing HIV with fewer resources. Generic versions of lamivudine, abacavir, and efavirenz became available in the United States within the past 6 years at prices lower than their brand-name counterparts, a generic version of PrEP (emtricitabine and tenofovir disoproxil fumarate) was approved in 2016, and generic versions of tenofovir disoproxil are expected later in 2018. Yet most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries…